Acalabrutinib

Drug Profile

Acalabrutinib

Alternative Names: ACP-196

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; Merck Sharp & Dohme
  • Class Antineoplastics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Bladder cancer; Head and neck cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis
  • Phase I/II B cell lymphoma; B cell prolymphocytic leukaemia; Glioblastoma; Waldenstrom's macroglobulinaemia
  • Phase I Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma

Most Recent Events

  • 09 Mar 2017 University Hospital Southampton NHS Foundation Trust plans the ACCEPT phase I/II trial for Diffuse large B-cell lymphoma in United Kingdom
  • 05 Dec 2016 Updated preliminary efficacy and adverse events data from a phase I/II trial in Chronic lymphocytic leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top